Breaking News

Accure Therapeutics Launches with €7.6M Series A Round

Alta Life Sciences and CDTI invest in new company that will develop portfolio of new medicines to address CNS diseases

By: Contract Pharma

Contract Pharma Staff

Accure Therapeutics, a new pharma R&D player in the central nervous system (CNS) field, has launched operations with a Series A round of funding totaling €7.6 million ($8.1M). The funding round was led by Alta Life Sciences and supported by the Centre for Technological and Industrial Development (CDTI). The company will develop a portfolio of new drug candidates to treat CNS diseases, supported by a seasoned team with solid pharma and biotech experience, who will run operations.   According ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters